Pacira Pharmaceuticals Inc. (PCRX) Stock Rating Reaffirmed by Cowen and Company

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “hold” rating reaffirmed by stock analysts at Cowen and Company in a report issued on Friday.

The analysts wrote, “Pacira Pharmaceuticals Receives a Hold from Cowen & Co. | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h<i.length;h++)c.supports[i[h]]=d(i[h]),c.supports.everything=c.supports.everything&&c.supports[i[h]],"flag"!==i[h]&&(c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&c.supports[i[h]]);c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&!c.supports.flag,c.DOMReady=!1,c.readyCallback=function(){c.DOMReady=!0},c.supports.everything||(g=function(){c.readyCallback()},b.addEventListener?(b.addEventListener("DOMContentLoaded",g,!1),a.addEventListener("load",g,!1)):(a.attachEvent("onload",g),b.attachEvent("onreadystatechange",function(){"complete"===b.readyState&&c.readyCallback()})),f=c.source||{},f.concatemoji?e(f.concatemoji):f.wpemoji&&f.twemoji&&(e(f.twemoji),e(f.wpemoji)))}(window,document,window._wpemojiSettings);

img.wp-smiley,
img.emoji {
display: inline !important;
border: none !important;
box-shadow: none !important;
height: 1em !important;
width: 1em !important;
margin: 0 .07em !important;
vertical-align: -0.1em !important;
background: none !important;
padding: 0 !important;
}

/* */

<!–
var a2a_config=a2a_config||{},wpa2a={done:false,html_done:false,script_ready:false,script_load:function(){var a=document.createElement('script'),s=document.getElementsByTagName('script')[0];a.type='text/javascript';a.async=true;a.src='http://static.addtoany.com/menu/page.js';s.parentNode.insertBefore(a,s);wpa2a.script_load=function(){};},script_onready:function(){wpa2a.script_ready=true;if(wpa2a.html_done)wpa2a.init();},init:function(){for(var i=0,el,target,targets=wpa2a.targets,length=targets.length;i

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘http://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=e20e19e287&wpp_id=456309’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Pacira Pharmaceuticals Receives a Hold from Cowen & Co.”

PCRX has been the subject of a number of other reports. Mizuho reaffirmed a “buy” rating and set a $64.00 price target on shares of Pacira Pharmaceuticals in a report on Tuesday, August 2nd. Zacks Investment Research raised Pacira Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 price target for the company in a report on Wednesday, August 10th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $81.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, August 3rd. Brean Capital reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a report on Friday, August 5th. Finally, Wedbush reaffirmed an “outperform” rating and set a $109.00 price target on shares of Pacira Pharmaceuticals in a report on Tuesday, September 27th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $72.83.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 33.65 on Friday. The company’s 50-day moving average price is $37.54 and its 200 day moving average price is $43.41. The firm’s market capitalization is $1.25 billion. Pacira Pharmaceuticals has a 52-week low of $31.08 and a 52-week high of $80.25.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Thursday, August 4th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.16. Pacira Pharmaceuticals had a positive return on equity of 0.02% and a negative net margin of 4.21%. The business earned $69.60 million during the quarter, compared to analysts’ expectations of $67.80 million. During the same period in the prior year, the firm posted $0.20 EPS. Pacira Pharmaceuticals’s quarterly revenue was up 17.8% compared to the same quarter last year. Equities analysts predict that Pacira Pharmaceuticals will post $0.44 earnings per share for the current fiscal year.

In other news, CEO David M. Stack sold 15,000 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $45.32, for a total value of $679,800.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, President James S. Scibetta sold 25,000 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $45.21, for a total value of $1,130,250.00. The disclosure for this sale can be found here. 6.90% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of PCRX. Fox Run Management L.L.C. raised its position in Pacira Pharmaceuticals by 0.8% in the third quarter. Fox Run Management L.L.C. now owns 13,400 shares of the company’s stock valued at $459,000 after buying an additional 100 shares in the last quarter. Fisher Asset Management LLC raised its position in Pacira Pharmaceuticals by 1.4% in the third quarter. Fisher Asset Management LLC now owns 6,282 shares of the company’s stock valued at $215,000 after buying an additional 85 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in Pacira Pharmaceuticals by 111.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,051 shares of the company’s stock valued at $104,000 after buying an additional 1,607 shares in the last quarter. American Century Companies Inc. raised its position in Pacira Pharmaceuticals by 0.3% in the second quarter. American Century Companies Inc. now owns 66,391 shares of the company’s stock valued at $2,239,000 after buying an additional 206 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Pacira Pharmaceuticals by 16.5% in the second quarter. Legal & General Group Plc now owns 8,985 shares of the company’s stock valued at $322,000 after buying an additional 1,270 shares in the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

5 Day Chart for NASDAQ:PCRX

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Disney to Build Larger Hong Kong Kingdom
Disney to Build Larger Hong Kong Kingdom
DraftKings and FanDuel Finally Will Merge
DraftKings and FanDuel Finally Will Merge


 
© 2006-2016 Ticker Report. Google+.